A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis

References

• Goff KL, Karimkhani C, Boyers LN, et al. The global burden of psoriatic skin disease. Br J Dermatol 2015;172:1665-8
   PubMed Web of Science ®Google Scholar
• Australian Bureau of Statistics. National Health Survey: First results, 2014–15. ABS; Canberra, Australia. 2015. Available at: http://www.abs.gov.au/AUSSTATS/[email protected]/DetailsPage/4364.0.55.0012014-15?OpenDocument. Accessed June 14, 2017
   Google Scholar
• Baker C, Mack A, Cooper A, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. Austral J Dermatol 2013;54:148-54
   Web of Science ®Google Scholar
• Armstrong AW, Robertson AD, Wu J, et al. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003–2011. JAMA Dermatol 2013;149:1180-5
   PubMed Web of Science ®Google Scholar
• Mercy KM, Gordon KB, Paller AS. Patient satisfaction and quality of life in psoriasis and psoriatic arthritis. JAMA Dermatol 2014;312:2676-7
   Google Scholar
• Kragballe K, Austad J, Barnes L, et al. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006;154:1155-60
   PubMed Web of Science ®Google Scholar
• Kragballe K, Austad J, Barnes L, et al. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006;213:319-26
   PubMed Web of Science ®Google Scholar
• Lambert J, Hol CW, Vink J. Real-life effectiveness of once-daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52-week PRO-long study. J Eur Acad Dermatol Venereol 2015;29:2349-55
   PubMed Web of Science ®Google Scholar
• Luger TA, Cambazard F, Larsen FG, et al. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008 217:321-8
   PubMed Web of Science ®Google Scholar
• Laws PM, Young HS. Topical treatment of psoriasis. Expert Opin Pharmacother 2010;11:1999-2009
   PubMed Web of Science ®Google Scholar
• Augustin M, Peeters P, Radtke M, et al. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of calcipotriol/betamethasone (Daivobet/Dovobet/Taclonex) once daily and a morning/evening nnon-fix combination of calcipotriol and betamethasone. Dermatology 2007;215:219-28
   PubMed Web of Science ®Google Scholar
• Augustin M, Radtke M, van Engen A, et al. Pharmacoeconomic model of topical treatment options of mild to moderate psoriasis vulgaris in Germany. J Dtsch Dermatol Ges 2009;7:329-38
   PubMed Web of Science ®Google Scholar
• Holm MV, Ekman M, Ryttov J. The cost-effectiveness of a new gel formulation of calcipotriol/betamethasone dipropionate for the treatment of scalp psoriasis in Norway. Value Health 2010;13:A399
   Google Scholar
• Affleck AG, Bottomley JM, Auland M, et al. Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel in the treatment of scalp psoriasis in Scotland. Curr Med Res Opin 2011;27:269-84
   PubMed Web of Science ®Google Scholar
• Bottomley JM, Auland ME, Morais J, et al. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis. Curr Med Res Opin 2007;23:1887-901
   PubMed Web of Science ®Google Scholar
• Colombo GL, Di Matteo S, Bruno G, et al. Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation. Clinicoecon Outcomes Res 2012;4:261-8
   PubMedGoogle Scholar
• Hollesen Basse L, Olesen M, Lacour JP, et al. Enhanced in vitro skin penetration and antipsoriatic effect of fixed combination calcipotriol plus betamethasone dipropionate in an innovative foam vehicle. J Invest Dermatol 2014;134(S33):Abstract 192
   Google Scholar
• Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol 2016;31:1-8
   Web of Science ®Google Scholar
• Pharmaceutical Benefits Advisory Committee (PBAC). Guidelines for preparing a submission to the Pharmaceutical Benefits Advisory Committee. Version 5.0. Canberra, Australia: PBAC: 2016. Available at: https://pbac.pbs.gov.au/content/information/files/pbac-guidelines-version-5.pdf. Accessed June 14, 2017
   Google Scholar
• LEO Pharma A/S. Clinical study report LP0053-1003: LEO 90100 aerosol foam compared to calcipotriol plus betamethasone dipropionate gel in subjects with psoriasis vulgaris. LEO Pharma A/S; 2015. Ballerup, Denmark. Available at: http://www.leo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical%20trial%20summaries%20and%20reports/LP0053-1003_CSR.pdf
   Google Scholar
• Freeman K, Marum M, Bottomley JM, et al. A psoriasis-specific model to support decision making in practice - UK experience. Curr Med Res Opin 2011;27:205-23
   PubMed Web of Science ®Google Scholar
• Sawyer L, Samarasekera EJ, Wonderling D, et al. Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis. Br J Dermatol 2013;168:1095-105
   PubMed Web of Science ®Google Scholar
• Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 2011;25(Suppl 4):9-14
   PubMed Web of Science ®Google Scholar
• Quintiles IMS. Daivobet^® market share development since launch. Data on file with LEO Pharma A/G; 2017. Ballerup, Denmark.
   Google Scholar
• Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64(Suppl II):ii65-ii8
   PubMedGoogle Scholar
• Pharmaceutical Benefits Advisory Committee (PBAC). Public summary document. CALCIPOTRIOL + BETAMETHASONE DIPROPIONATE gel 50/500, 30g and 60g Daivobet®, Leo Pharma Pty Ltd.; 2015. Canberra, Australia. Available at: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2015-11/calcipotriol-betamethasone-dipropionate-daivobet-psd-11-2015
   Google Scholar
• Pharmaceutical Benefits Advisory Committee (PBAC). Public summary document. CALCIPOTRIOL with BETAMETHASONE, foam containing calcipotriol 50 micrograms with betamethasone 500 micrograms (as dipropionate) per g, 60 g, Enstilar^®. Commonwealth of Australia; 2017. Canberra, Australia. Available at: http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2016-11/calcipotriol-with-betamethasone-psd-november-2016
   Google Scholar
• Langley RG, Gupta A, Papp K, et al. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology 2011;222:148-56
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Benefits Scheme. Calcipotriol 0.005% + Betamethasone (as dipropionate) 0.05% foam, 60 g. Australian Government Department of Health; 2017. Canberra, Australia. Available at: http://www.pbs.gov.au/medicine/item/11091R. [Last accessed 22 November 2017]
   Google Scholar
• Fleming C, Ganslandt C, Guenther L, et al. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010;20:465-71
   PubMed Web of Science ®Google Scholar
• LEO Pharma A/S. A phase 2 study comparing treatment with LEO 90100 with calcipotriol plus betamethasone ointment, LEO 90100 vehicle and ointment vehicle in subjects with psoriasis vulgaris. 2013. Ballerup, Denmark. Available at: http://leo-pharma.com/Files/Filer/LEO_corporate_downloads/Clinical%20trial%20summaries%20and%20reports/LEO-90100-35_CSR.pdf
   Google Scholar
• Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients With psoriasis vulgaris—a randomized phase III study (PSO-FAST). J Drugs Dermatol 2015;14:1468-77
   PubMed Web of Science ®Google Scholar
• Medicare Benefits Schedule (MBS). Medicare Benefits Schedule Book. Operating from 01 July 2017. Canberra, Australia: Australian Government Department of Health; 2017
   Google Scholar
• Griffiths CEM, Stein Gold L, Cambazard F, et al. Greater improvement in quality of life outcomes in patients using fixed-combination calcipotriol plus betamethasone dipropionate aerosol foam versus gel: results from the PSO-ABLE study. Eur J Dermatol 2018 (in press)
   Google Scholar
• Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study. J Dermatolog Treat 2016;27:120-7
   PubMed Web of Science ®Google Scholar
• Taylor C, Jan S. Economic evaluation of medicines. Aust Prescr 2017;40:76-8
   PubMed Web of Science ®Google Scholar
• Scottish Medicines Consortium. Calcipotriol 50 micrograms/g and betamethasone 0.5mg/g cutaneous foam (Enstilar). SMC; 2016. Glasgow, UK. Available at: https://www.scottishmedicines.org.uk/files/advice/calcipotriol_betamethasone__Enstilar__Abb_FINAL_August_2016_for_website.pdf. [Last accessed 21 August 2017]
   Google Scholar
• Dental and Pharmaceutical Benefits Agency. Enstilar (kalcipotriol och betametason). DPBA; 2016. Canberra, Australia. Available online at: https://www.tlv.se/Upload/Beslut_2016/bes160923_enstilar.pdf. [Last accessed 21 August 2017]
   Google Scholar
• Pharmaceutical Benefits Scheme. Calcipotriol 0.005% + betamethasone (as dipropionate) 0.05% gel, 60 g. Canberra, Australia. Australian Government Department of Health; 2017. Available at: http://www.pbs.gov.au/medicine/item/10075G. [Last accessed 22 November, 2017]
   Google Scholar
• Chemistwarehouse.com.au. Cortic DS Cream 1% 30g. Virginia, Australia; 2017. Available at: http://www.chemistwarehouse.com.au. [Last accessed 22 November, 2017]
   Google Scholar